{"protocolSection": {"identificationModule": {"nctId": "NCT00455923", "orgStudyIdInfo": {"id": "SAM103976"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)", "officialTitle": "SERETIDE vs FLIXOTIDE in Mild Persistent Asthma (GINAII)"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-05-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2007-07-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-07-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-04-03", "studyFirstSubmitQcDate": "2007-04-03", "studyFirstPostDateStruct": {"date": "2007-04-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-07-23", "resultsFirstSubmitQcDate": "2017-07-23", "resultsFirstPostDateStruct": {"date": "2018-01-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-01-09", "lastUpdatePostDateStruct": {"date": "2018-02-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be up-titrated until well controlled is achieved, After 6 months the treatment continues without changes during 9 months = PhaseII. The aim is to investigate and evaluate the assumption that the combination therapy with SERETIDE controls mild persistent asthma better than inhaled corticosteroids(FLIXOTIDE) alone."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma", "exacerbation", "persistent", "bronchial hyperresponsiveness", "mild", "GINAII"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT"}, "enrollmentInfo": {"count": 100, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Seretide", "type": "EXPERIMENTAL", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.", "interventionNames": ["Drug: Seretide"]}, {"label": "Flixotide", "type": "EXPERIMENTAL", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.", "interventionNames": ["Drug: Flixotide"]}], "interventions": [{"type": "DRUG", "name": "Seretide", "description": "Seretide", "armGroupLabels": ["Seretide"]}, {"type": "DRUG", "name": "Flixotide", "description": "Flixotide", "armGroupLabels": ["Flixotide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants in Each Arm With a Need for an Increase in Study Medication", "description": "During the first 6 months, when the asthma was unstable/uncontrolled, dose of Seretide (Sal/FP) was increased from 50/100 mcg in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). Also, dose of Flixotide (FP only), was increased from 100 mcg to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months. Number of participants in each arm with a need for an increase in study medication are presented.", "timeFrame": "Up to 18 months"}], "secondaryOutcomes": [{"measure": "Absolute Bronchial Hyper-responsiveness up to 18 Months", "description": "Data for this outcome measure was not collected.", "timeFrame": "Up to 18 months"}, {"measure": "Change in Bronchial Hyper-responsiveness From Baseline to 18 Months", "description": "Data for this outcome measure was not collected.", "timeFrame": "Baseline (Day 0) to 18 months"}, {"measure": "Number of Symptom-free Days and Nights Without Use of Rescue Medication", "description": "The rescue medications used for exacerbations included Ventoline Diskus\u00ae 200 mcg/dose inhalations as required and oral Prednisolone 25 mg per day for five days, and when necessary, ten days. Data for this outcome measure was not collected.", "timeFrame": "Up to 18 months"}, {"measure": "Number of Exacerbations: in Total and by Degree of Severity", "description": "Severe exacerbation: needed hospitalization/emergency unit visit. Moderate exacerbation: Needed oral cortico-steroid or adding inhaled Flixotide to maintenance study medicine; decrease in morning or evening peak expiratory flow (PEF) \\> 30% during \u2265 2 following days from Baseline (Day 0). Mild exacerbation: any night symptoms \u2265 3 consecutive, or night symptoms \u2265 2 consecutive nights in case symptoms have been scored \u2265 2 during at least one night, Day symptoms scored \u2265 2 during \u2265 4 following days, or Day symptoms scored \u2265 3 during \u2265 3 following days, or Day symptoms scored \u2265 4 during \u2265 2 following days, or rescue medication use \u2265 2 occasions per day for \u2265 4 following days, or rescue medication use \u2265 3 occasions per day for \u2265 3 following days, or rescue medication use \u2265 4 occasions per day for \u2265 2 following days, or decrease in morning/evening PEF \\>20% during \u2265 2 following days from Baseline (Day 0). Number of total exacerbations and severe, moderate and mild exacerbations are presented.", "timeFrame": "Up to 18 months"}, {"measure": "Time to Increase of Study Medication", "description": "Data for this outcome measure was not collected.", "timeFrame": "Up to 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Willing to give informed consent.\n* Males or females aged 18-70.\n* Able to understand and complete dairy cards.\n* Mild persistent asthma according to GINA. In addition, at randomisation subjects were required to have: 1. Day time symptoms more than once a week but not every day. 2. Night-time symptoms not more than once a week. 3. FEV1 \\>80% predicted 4. PC20 \\<8mg/mL\n\nExclusion Criteria:\n\n* Change to regular asthma medication in 4-weeks prior to visit 1.\n* Use of oral, depot or parenteral corticosteroids within 8 weeks of visit 1.\n* Lower respiratory tract within 4 weeks of Visit 1\n* Received investigational study drug within 4 weeks of visit\n* Smoking history of \\>10 pack years of more.\n* Serious uncontrolled disease.\n* Medical conditions or medications known to affect the assessments or endpoints.\n* Evidence of alcohol or drug abuse.\n* Known pregnancy or planned pregnancy.\n* Known or suspected hypersensitivity to inhaled corticosteroids, beta-agonists or lactose.\n* Previous enrollment in the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Lule\u00e5", "zip": "SE-971 89", "country": "Sweden", "geoPoint": {"lat": 65.58415, "lon": 22.15465}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This study was conducted at a single center with two sites in Sweden from May 2005 to July 2007. Seretide Diskus\u00ae, Flixotide\u00ae and Ventoline Diskus\u00ae are the registered products of GlaxoSmithKline.", "groups": [{"id": "FG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 micrograms (mcg) Seretide (combination of salmeterol/fluticasone propionate (Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "FG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "47"}, {"groupId": "FG001", "numSubjects": "47"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "BG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "100"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": ">=18 to 70 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "100"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "63"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "100"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants in Each Arm With a Need for an Increase in Study Medication", "description": "During the first 6 months, when the asthma was unstable/uncontrolled, dose of Seretide (Sal/FP) was increased from 50/100 mcg in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). Also, dose of Flixotide (FP only), was increased from 100 mcg to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months. Number of participants in each arm with a need for an increase in study medication are presented.", "populationDescription": "Intent-to-Treat (ITT) Population which comprised of all participants who were randomized and received at least one dose of the study medication.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 18 months", "groups": [{"id": "OG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "OG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Bronchial Hyper-responsiveness up to 18 Months", "description": "Data for this outcome measure was not collected.", "populationDescription": "Data for this outcome measure was not collected.", "reportingStatus": "POSTED", "timeFrame": "Up to 18 months", "groups": [{"id": "OG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "OG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change in Bronchial Hyper-responsiveness From Baseline to 18 Months", "description": "Data for this outcome measure was not collected.", "populationDescription": "ITT population. Data for this outcome measure was not collected.", "reportingStatus": "POSTED", "timeFrame": "Baseline (Day 0) to 18 months", "groups": [{"id": "OG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "OG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Number of Symptom-free Days and Nights Without Use of Rescue Medication", "description": "The rescue medications used for exacerbations included Ventoline Diskus\u00ae 200 mcg/dose inhalations as required and oral Prednisolone 25 mg per day for five days, and when necessary, ten days. Data for this outcome measure was not collected.", "populationDescription": "ITT population. Data for this outcome measure was not collected.", "reportingStatus": "POSTED", "timeFrame": "Up to 18 months", "groups": [{"id": "OG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "OG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Number of Exacerbations: in Total and by Degree of Severity", "description": "Severe exacerbation: needed hospitalization/emergency unit visit. Moderate exacerbation: Needed oral cortico-steroid or adding inhaled Flixotide to maintenance study medicine; decrease in morning or evening peak expiratory flow (PEF) \\> 30% during \u2265 2 following days from Baseline (Day 0). Mild exacerbation: any night symptoms \u2265 3 consecutive, or night symptoms \u2265 2 consecutive nights in case symptoms have been scored \u2265 2 during at least one night, Day symptoms scored \u2265 2 during \u2265 4 following days, or Day symptoms scored \u2265 3 during \u2265 3 following days, or Day symptoms scored \u2265 4 during \u2265 2 following days, or rescue medication use \u2265 2 occasions per day for \u2265 4 following days, or rescue medication use \u2265 3 occasions per day for \u2265 3 following days, or rescue medication use \u2265 4 occasions per day for \u2265 2 following days, or decrease in morning/evening PEF \\>20% during \u2265 2 following days from Baseline (Day 0). Number of total exacerbations and severe, moderate and mild exacerbations are presented.", "populationDescription": "ITT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Exacerbations", "timeFrame": "Up to 18 months", "groups": [{"id": "OG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "OG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"title": "Total exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "74"}]}]}, {"title": "Severe exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Moderate exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Mild exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "52"}]}]}]}, {"type": "SECONDARY", "title": "Time to Increase of Study Medication", "description": "Data for this outcome measure was not collected.", "populationDescription": "ITT population. Data for this outcome measure was not collected.", "reportingStatus": "POSTED", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}, {"id": "OG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 18 months", "description": "Adverse events (Serious adverse events and non-serious adverse events) were collected and are reported for the ITT Population.", "eventGroups": [{"id": "EG000", "title": "Seretide", "description": "Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.", "deathsNumAffected": 0, "deathsNumAtRisk": 50, "seriousNumAffected": 3, "seriousNumAtRisk": 50, "otherNumAffected": 48, "otherNumAtRisk": 50}, {"id": "EG001", "title": "Flixotide", "description": "Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.", "deathsNumAffected": 0, "deathsNumAtRisk": 50, "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 47, "otherNumAtRisk": 50}], "seriousEvents": [{"term": "Colon diverticulitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 50}]}, {"term": "Migraine/headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 50}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 50}]}], "otherEvents": [{"term": "Common cold", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 39, "numAtRisk": 50}]}, {"term": "Upper airway infections", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 50}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 50}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 50}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 50}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 50}]}, {"term": "Mouth candida", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 50}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 50}]}, {"term": "Upper back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 50}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M18930", "name": "Bronchial Hyperreactivity", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Light touch", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "relevance": "LOW"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Interruption", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}